Press Releases Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
32.98 ^USD	+0.92%		-12.75%	+53.25%

May. 15	Spyre Therapeutics, Inc. Announces Board Changes	CI
May. 13	Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors	May. 16	AQ
Spyre Therapeutics: Q1 Earnings Snapshot	May. 09	AQ
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 09	PR
Spyre Therapeutics Announces Grants of Inducement Awards	May. 06	AQ
Spyre Therapeutics Announces Grants of Inducement Awards	May. 03	PR
Spyre Therapeutics Announces Grants of Inducement Awards	Apr. 01	PR
Spyre Therapeutics Announces Grants of Inducement Awards	Mar. 04	AQ
Spyre Therapeutics Announces Grants of Inducement Awards	Mar. 01	PR
Spyre Therapeutics: Q4 Earnings Snapshot	Feb. 29	AQ
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	PR
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	Feb. 26	PR
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	Feb. 09	AQ
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	Feb. 06	AQ
Spyre Therapeutics Announces Grants of Inducement Awards	Feb. 02	PR
Spyre Therapeutics Announces Grants of Inducement Awards	Dec. 22	PR
Spyre Therapeutics to Present at Upcoming Investor Conference	Nov. 29	AQ
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD	Nov. 28	AQ
Aeglea BioTherapeutics : Submission of Matters to a Vote of Security Holders - Form 8-K	Nov. 24	PU
Aeglea BioTherapeutics Announces Grants of Inducement Awards	Nov. 22	PR
Aeglea BioTherapeutics : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Form 8-K	Nov. 15	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Press Releases

Filters